Fig. 9: The tumor recurrence and metastasis inhibition of FP NPs in H1975-luc tumor-bearing mice.

a Schematic illustration of the experimental design. b The tumor volumes of mice during treatments with each group (n = 7 mice per group; two-way ANOVA followed by Tukey’s multiple comparisons post test). c The body weight of mice during treatments with each group (n = 7 mice per group; two-way ANOVA followed by Tukey’s multiple comparisons post test). d Tumor volume changes for each mouse in each group (n = 7 mice per group). e In vivo bioluminescence imaging of tumor-bearing mice receiving various treatments after surgery. Three representative mice in each treatment group are shown. Images of day 0 were taken on the day of surgery. f The final anatomical picture and H&E staining of the lungs (n = 3 independent samples; Scale bars, 5 mm). g IHC of p53, E-cadherin, MMP-2, MMP-9, Vimentin in the primary tumor tissues of cisplatin or FP NPs treatment, and recurrent and metastatic tumor tissues of cisplatin treatment (n = 3 independent samples). Scale bars, 20 μm. h Recurrence tumor weights of different groups on day 42 after surgery (n = 7 mice per group; one-way ANOVA followed by Tukey’s HSD post hoc test). i Kaplan-Meier survival curve of mice treated with each group over 65 days (n = 7 mice per group; Log-rank Mantel–Cox test). j Final weights of the heart, liver, spleen, lungs, and kidneys (n = 7 mice per group;two-tailed unpaired t test). k Heatmap of TNF-α, VEGF, IL-10 and IL-6 expression profiles in serum (n = 3 mice per group). l Indicators of routine blood examination (n = 3 mice per group; two-tailed unpaired t test) of mice. Data are shown as the mean ± SD; n.s. no significance. Source data are provided as a Source Data file.